Table 3 Clinical characteristics of investigated group divided by sex
Compared groups and clinical data | Females | Males | Statistical significance p |
|---|---|---|---|
n = 40 | n = 25 | ||
Age (years) | 57.9 ± 11.0 | 52.6 ± 12.3 | NS |
Hypertension | 34 (85.0%) | 20 (80.0%) | NS |
Ischemic heart disease | 9 (22.5%) | 11 (44.0%) | NS |
Myocardial infarct | 2 (5.0%) | 6 (24.0%) | p < 0.05 |
Cardiac failure | 18 (45.0%) | 7 (28.0%) | p < 0.05 |
IFG/IGT | 21 (52.5%) | 17 (68.0%) | NS |
CKD | 13 (32.5%) | 2 (8.0%) | p < 0.05 |
Stroke | 2 (5.0%) | 1 (4.0%) | NS |
Cerebral arteries failure | 0 | 3 (12.0%) | p = 0.053 |
Hyperuricemia | 17 (42.5%) | 14 (56.0%) | NS |
Dyslipidemia | 37 (92.5%) | 24 (96.0%) | NS |
Tobacco smoking | 2 (5.0%) | 3 (12.0%) | NS |
ACEI | 31 (77.5%) | 15 (60.0%) | NS |
ARB | 13 (32.5%) | 4 (16.0%) | NS |
Diuretics | 27 (67.5%) | 10 (40.0%) | p < 0.05 |
CCA | 12 (30.0%) | 7 (28.0%) | NS |
BB | 17 (42.5%) | 8 (32.0%) | NS |
Spironolactone | 14 (35.0%) | 4 (16.0%) | NS |
ARA | 1 (2.5%) | 6 (24.0%) | p = 0.01 |
ASA | 10 (25.0%) | 7 (28.0%) | NS |
Hypolipemic treatment a | 20 (50.0%) | 15 (60.0%) | NS |